As 2022 draws to a close, it is safe to say Wall Street won’t remember this year fondly. Economic problems such as inflation, a persistent pandemic, and geopolitical tensions are some factors contributing to the broader market’s poor performance this year. No one can predict when equities will recover, but when they do, it will pay to have skin in the game.
Buying undervalued stocks today could help investors beat the market in the next five years and beyond. Let’s look at two biotech stocks that look attractive at current levels: AbbVie (NYSE : ABBV) et Gilead Sciences (NASDAQ: GILD) .
Pour plus de détails, voir :Vous avez $1,000 ? 2 actions qui pourraient être des achats à bon marché en 2022 et au-delà